Mirna Therapeutics, a progressive, mainstream biotechnology company which specializes in the production and sale of microRNA, or miRNA as it is also known, has appointed Dr. Clay Siegall, as director of its Board of Directors as of January 30, 2013.
Dr. Siegall, who is co-co-founder and President of Seattle Genetics and carries numerous other titles and accomplishments, has embellished the oncology industry with a plethora of possible antibody based therapies up and coming, including his prize product thus far of ADCETRIS® (brentuximab vedotin) that has already been approved in August 2011. Thanks to Dr. Siegall‘s master-fundraising skills which secured 675 million dollars in private and public funding, his work continues to enhance the well-being of cancer patients world-wide.
What exactly are microRNAs? microRNAs dwell deep within the human genome and regulate global gene expression. Appearing to affect possible hundreds of different genes as sort of a main switch, microRNA seems to proficiently control and coordinate several cellular paths and mechanisms. This important function aids in appropriate embryonic development, enhancing immunity, soothing inflammation and encouraging cell growth and propagation. When miRNAs do not function properly, it appears to profoundly affect the initial start, growth and spread of several different cancers. It has been discovered that the replacement of impaired miRNAs within the cells of tumors creates a positive and therapeutic response in the patient.
What is Mirna Therapeutics? Mirna Therapeutics, founded in 2007 in Austin, Texas, is a biotechnology company that uses its own scientists to discover effective uses for miRNAs which have a positive impact in various diseases and cancer. In fact, in animal experiments it has been proven that miRNAs are very helpful at suppressing cancer growth.
The award-winning Dr. Clay Siegall is a trailblazer in the pharmaceutical, genome and oncology industry. He has many accomplishments and titles to his name including but not limited to: President and Co-founder of Seattle Genetics (which produced the powerful drug, ADCETRIS®), Board of Directors of Alder Biopharmaceuticals and Mirna Therapeutics, researcher at Bristol-Myers Squibb Pharmaceutical Research institute, researcher at the National Cancer Institute and the National Institutes of Health.
Dr. Siegall has written over 70 scientific publications and has 15 patents to his name. He Received his PH.D. in Genetics from George Washington University and at the University of Maryland. Some of his awards include the Pierce Award in 1995 for his work targeting toxins, and in 2002, he was an Ernst & Young Pacific Northwest Entrepreneur of the Year award finalist.